The DOI matches its Crossref record; 178 of the 178 references it cites were found in a registry or an index.
CCL5/CCR5 axis in human diseases and related treatments
Open accessAbstract
To defense harmful stimuli or maintain the immune homeostasis, the body produces and recruits a superfamily of cytokines such as interleukins, interferons, chemokines etc. Among them, chemokines act as crucial regulators in defense systems. CCL5/CCR5 combination is known for facilitating inflammatory responses, as well as inducing the adhesion and migration of different T cell subsets in immune responses. In addition, recent studies have shown that the interaction between CCL5 and CCR5 is involved in various pathological processes including inflammation, chronic diseases, cancers as well as the infection of COVID-19. This review focuses on how CCL5/CCR5 axis participates in the pathological processes of different diseases and their relevant signaling pathways for the regulation of the axis. Moreover, we highlighted the gene therapy and chemotherapy studies for treating CCR5-related diseases, including the ongoing clinical trials. The barriers and perspectives for future application and translational research were also summarized.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
Cell Migration: Integrating Signals from Front to Back
Ridley, A. J., Schwartz, M. A., Burridge, K., Firtel, R. A., Ginsberg, M. H., Borisy, G., Parsons, J. T., & Horwitz, A. R. (2003) · Science · doi:10.1126/science.1092053 · Cited by 4,978
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., Richardson, A. L., Polyak, K., Tubo, R., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06188 · Cited by 3,206
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008
Myeloid-Derived Suppressor Cells
Gabrilovich, D. I. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0297 · Cited by 1,882
Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation
Hütter, G., Nowak, D., Mossner, M., Ganepola, S., Müßig, A., Allers, K., Schneider, T., Hofmann, J., Kücherer, C., Blau, O., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0802905 · Cited by 1,837
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
Mendoza, M. C., Er, E. E., & Blenis, J. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2011.03.006 · Cited by 1,817
Immunity and Inflammation in Atherosclerosis
Wolf, D., & Ley, K. (2019) · Circulation Research · doi:10.1161/circresaha.118.313591 · Cited by 1,697
Targeting PI3K/Akt/mTOR Signaling in Cancer
Porta, C., Paglino, C., & Mosca, A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00064 · Cited by 1,485
Kim, K. H., & Roberts, C. W. M. (2016) · Nature Medicine · doi:10.1038/nm.4036 · Cited by 1,471 · cited 1×
“EZH2 could also be considered as an key regulator of macrophagemediated cancer cell progression and migration.(53,54) Moreover, HER2 and phosphatase and tensin homolog deleted on chromosome ten (PTEN) are a pair of cancerrelated proteins that are closely associated with metastasis.”
A guide to chemokines and their receptors
Hughes, C. E., & Nibbs, R. J. B. (2018) · The FEBS Journal · doi:10.1111/febs.14466 · Cited by 1,412
NF-κB in the liver—linking injury, fibrosis and hepatocellular carcinoma
Luedde, T., & Schwabe, R. F. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.213 · Cited by 1,345
Mechanisms and consequences of Jak–STAT signaling in the immune system
Villarino, A. V., Kanno, Y., & O'Shea, J. J. (2017) · Nature Immunology · doi:10.1038/ni.3691 · Cited by 1,221
NF-kB in development and progression of human cancer
Dolcet, X., Llobet, D., Pallares, J., & Matias-Guiu, X. (2005) · Virchows Archiv · doi:10.1007/s00428-005-1264-9 · Cited by 1,169
Targeting RAS–ERK signalling in cancer: promises and challenges
Samatar, A. A., & Poulikakos, P. I. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4281 · Cited by 1,163
Tumor-associated macrophages: an accomplice in solid tumor progression
Chen, Y., Song, Y., Du, W., Gong, L., Chang, H., & Zou, Z. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0568-z · Cited by 1,096
mTOR signalling and cellular metabolism are mutual determinants in cancer
Mossmann, D., Park, S., & Hall, M. N. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0074-8 · Cited by 1,088
Targeting PI3K/mTOR Signaling in Cancer
Arcaro, A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00084 · Cited by 1,024
Targeting tumor-associated macrophages in cancer
Pathria, P., Louis, T. L., & Varner, J. A. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.02.003 · Cited by 933
Research Progress on the Relationship between Atherosclerosis and Inflammation
Zhu, Y., Xian, X., Wang, Z., Bi, Y., Chen, Q., Han, X., Tang, D., & Chen, R. (2018) · Biomolecules · doi:10.3390/biom8030080 · Cited by 872
Risk for and consequences of endometriosis: A critical epidemiologic review
Shafrir, A. L., Farland, L. V., Shah, D. K., Harris, H. R., Kvaskoff, M., Zondervan, K., & Missmer, S. A. (2018) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2018.06.001 · Cited by 823
Tumor-Associated Macrophages and Neutrophils in Tumor Microenvironment
Kim, J., & Bae, J.-S. (2016) · Mediators of Inflammation · doi:10.1155/2016/6058147 · Cited by 802
The role of HIF in immunity and inflammation
McGettrick, A. F., & O’Neill, L. A. J. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.08.002 · Cited by 768
JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression
Owen, K. L., Brockwell, N. K., & Parker, B. S. (2019) · Cancers · doi:10.3390/cancers11122002 · Cited by 714
Atherosclerosis and inflammation: overview and updates
Geovanini, G. R., & Libby, P. (2018) · Clinical Science · doi:10.1042/cs20180306 · Cited by 703
Wen, Y., Lambrecht, J., Ju, C., & Tacke, F. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00558-8 · Cited by 695 · cited 1×
“These cellular and molecular processes could facilitate hepatic inflammation.(79,80) New studies have shown that, CCL5/CCR5 interaction can accelerate hepatic inflammation process via NF-kB pathway.”
Korkaya, H., Kim, G.-I., Davis, A., Malik, F., Henry, N. L., Ithimakin, S., Quraishi, A. A., Tawakkol, N., D'Angelo, R., Paulson, A. K., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.06.014 · Cited by 538
Roles of regulatory T cells in cancer immunity
Takeuchi, Y., & Nishikawa, H. (2016) · International Immunology · doi:10.1093/intimm/dxw025 · Cited by 523
Breast Cancer–Associated PIK3CA Mutations Are Oncogenic in Mammary Epithelial Cells
Isakoff, S. J., Engelman, J. A., Irie, H. Y., Luo, J., Brachmann, S. M., Pearline, R. V., Cantley, L. C., & Brugge, J. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2612 · Cited by 509
Metabolic control of adult neural stem cell activity by Fasn-dependent lipogenesis
Knobloch, M., Braun, S. M. G., Zurkirchen, L., von Schoultz, C., Zamboni, N., Araúzo-Bravo, M. J., Kovacs, W. J., Karalay, Ö., Suter, U., Machado, R. A. C., et al. (2013) · Nature · doi:10.1038/nature11689 · Cited by 499
Halama, N., Zoernig, I., Berthel, A., Kahlert, C., Klupp, F., Suarez-Carmona, M., Suetterlin, T., Brand, K., Krauss, J., Lasitschka, F., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.005 · Cited by 495
Hodgkin lymphoma: A review and update on recent progress
Shanbhag, S., & Ambinder, R. F. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21438 · Cited by 481
The Pathogenesis of Endometriosis: Molecular and Cell Biology Insights
Laganà, A. S., Garzon, S., Götte, M., Viganò, P., Franchi, M., Ghezzi, F., & Martin, D. C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225615 · Cited by 479
GSK3 and its interactions with the PI3K/AKT/mTOR signalling network
Hermida, M. A., Dinesh Kumar, J., & Leslie, N. R. (2017) · Advances in Biological Regulation · doi:10.1016/j.jbior.2017.06.003 · Cited by 477
Chemokine up-regulation in SARS-coronavirus–infected, monocyte-derived human dendritic cells
Law, H. K. W., Cheung, C. Y., Ng, H. Y., Sia, S. F., Chan, Y. O., Luk, W., Nicholls, J. M., Peiris, J. S. M., & Lau, Y. L. (2005) · Blood · doi:10.1182/blood-2004-10-4166 · Cited by 471
CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia
Xu, L., Wang, J., Liu, Y., Xie, L., Su, B., Mou, D., Wang, L., Liu, T., Wang, X., Zhang, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817426 · Cited by 454 · cited 3×
“At present, there are lots of techniques that can be implemented into the therapies against such diseases, like zinc finger nuclease (ZFN), TALEN, 185 ribozyme, 186 shRNA 187 and CRISPR/Cas9.”
InfluentialPlasminogen activation and cancer
Behrendt, N., Høyer-Hansen, G., Johnsen, M., Lund, L. R., Ploug, M., Rømer, J., & Danø, K. (2005) · Thrombosis and Haemostasis · doi:10.1160/th05-01-0054 · Cited by 452
Tan, M. C. B., Goedegebuure, P. S., Belt, B. A., Flaherty, B., Sankpal, N., Gillanders, W. E., Eberlein, T. J., Hsieh, C.-S., & Linehan, D. C. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.3.1746 · Cited by 450 · cited 1×
“121,122 By the way, MDSCs are also characterized with powerful immuno-suppress function, resist not only the innate, but also the acquired immune cells functions.”
The Inflammatory Chemokine CCL5 and Cancer Progression
Aldinucci, D., & Colombatti, A. (2014) · Mediators of Inflammation · doi:10.1155/2014/292376 · Cited by 438
Schlecker, E., Stojanovic, A., Eisen, C., Quack, C., Falk, C. S., Umansky, V., & Cerwenka, A. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201018 · Cited by 438
CCR1 and CCR5 promote hepatic fibrosis in mice
Seki, E., De Minicis, S., Gwak, G.-Y., Kluwe, J., Inokuchi, S., Bursill, C. A., Llovet, J. M., Brenner, D. A., & Schwabe, R. F. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37444 · Cited by 431
DNA methylation controls the timing of astrogliogenesis through regulation of JAK-STAT signaling
Fan, G., Martinowich, K., Chin, M. H., He, F., Fouse, S. D., Hutnick, L., Hattori, D., Ge, W., Shen, Y., Wu, H., et al. (2005) · Development · doi:10.1242/dev.01912 · Cited by 417
PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment
Guerrero-Zotano, A., Mayer, I. A., & Arteaga, C. L. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9637-x · Cited by 417
Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer
Schödel, J., Grampp, S., Maher, E. R., Moch, H., Ratcliffe, P. J., Russo, P., & Mole, D. R. (2016) · European Urology · doi:10.1016/j.eururo.2015.08.007 · Cited by 405
Treg Heterogeneity, Function, and Homeostasis
Shevyrev, D., & Tereshchenko, V. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03100 · Cited by 404
The CCL5/CCR5 Axis in Cancer Progression
Aldinucci, D., Borghese, C., & Casagrande, N. (2020) · Cancers · doi:10.3390/cancers12071765 · Cited by 400
PI3K/AKT/mTOR signaling in gastric cancer: Epigenetics and beyond
Fattahi, S., Amjadi-Moheb, F., Tabaripour, R., Ashrafi, G. H., & Akhavan-Niaki, H. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118513 · Cited by 400
Glass, W. G., Lim, J. K., Cholera, R., Pletnev, A. G., Gao, J.-L., & Murphy, P. M. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20042530 · Cited by 391
Targeting CCL5 in inflammation
Marques, R. E., Guabiraba, R., Russo, R. C., & Teixeira, M. M. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.837886 · Cited by 384
Ratziu, V., Sanyal, A., Harrison, S. A., Wong, V. W., Francque, S., Goodman, Z., Aithal, G. P., Kowdley, K. V., Seyedkazemi, S., Fischer, L., et al. (2020) · Hepatology · doi:10.1002/hep.31108 · Cited by 378
Regulation and function of the RSK family of protein kinases
Romeo, Y., Zhang, X., & Roux, P. P. (2012) · Biochemical Journal · doi:10.1042/bj20110289 · Cited by 377
MicroRNAs Reprogram Normal Fibroblasts into Cancer-Associated Fibroblasts in Ovarian Cancer
Mitra, A. K., Zillhardt, M., Hua, Y., Tiwari, P., Murmann, A. E., Peter, M. E., & Lengyel, E. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0206 · Cited by 371
Cimino-Mathews, A., Thompson, E., Taube, J. M., Ye, X., Lu, Y., Meeker, A., Xu, H., Sharma, R., Lecksell, K., Cornish, T. C., et al. (2016) · Human Pathology · doi:10.1016/j.humpath.2015.09.003 · Cited by 336
Liver Macrophages: Old Dogmas and New Insights
Guillot, A., & Tacke, F. (2019) · Hepatology Communications · doi:10.1002/hep4.1356 · Cited by 335
Alonso, S. R., Tracey, L., Ortiz, P., Pérez-Gómez, B., Palacios, J., Pollán, M., Linares, J., Serrano, S., Sáez-Castillo, A. I., Sánchez, L., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3481 · Cited by 326
Lefebvre, E., Moyle, G., Reshef, R., Richman, L. P., Thompson, M., Hong, F., Chou, H.-L., Hashiguchi, T., Plato, C., Poulin, D., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0158156 · Cited by 323 · cited 1×
“Nowadays, cenicriviroc-related clinical trials have demonstrated that the drug has both antiviral and anti-fibrosis effects in the condition of infections, non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) (NCT02653625) and many other conditions.(172,173) In NASH clinical trial (NCT02217475),…”
CCR5 is a receptor for Staphylococcus aureus leukotoxin ED
Alonzo III, F., Kozhaya, L., Rawlings, S. A., Reyes-Robles, T., DuMont, A. L., Myszka, D. G., Landau, N. R., Unutmaz, D., & Torres, V. J. (2013) · Nature · doi:10.1038/nature11724 · Cited by 291 · cited 1×
“Other infections Besides, Toxoplasma gondii and Staphylococcus aureus are able to kill cells without triggering host immune response by taking advantage of CCL5/CCR5 axis.(88) Conversely, CCR5 in West Nile virus (WNV) infection plays an antiviral role.”
CCR5 Antagonist Blocks Metastasis of Basal Breast Cancer Cells
Velasco-Velázquez, M., Jiao, X., De La Fuente, M., Pestell, T. G., Ertel, A., Lisanti, M. P., & Pestell, R. G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3917 · Cited by 282
Platelet-derived chemokines in inflammation and atherosclerosis
Bakogiannis, C., Sachse, M., Stamatelopoulos, K., & Stellos, K. (2019) · Cytokine · doi:10.1016/j.cyto.2017.09.013 · Cited by 281
Riccio, L. D. G. C., Santulli, P., Marcellin, L., Abrão, M. S., Batteux, F., & Chapron, C. (2018) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2018.01.010 · Cited by 279
Sef Is a Spatial Regulator for Ras/MAP Kinase Signaling
Torii, S., Kusakabe, M., Yamamoto, T., Maekawa, M., & Nishida, E. (2004) · Developmental Cell · doi:10.1016/j.devcel.2004.05.019 · Cited by 278
GSK-3β in DNA repair, apoptosis, and resistance of chemotherapy, radiotherapy of cancer
Lin, J., Song, T., Li, C., & Mao, W. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2020.118659 · Cited by 268
Psychosocial Factors and Inflammation in the Multi-Ethnic Study of Atherosclerosis
Ranjit, N. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.2.174 · Cited by 260
Chemokines in Vascular Dysfunction and Remodeling
Schober, A. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.161224 · Cited by 257
Blockade of Lymphocyte Chemotaxis in Visceral Graft-versus-Host Disease
Reshef, R., Luger, S. M., Hexner, E. O., Loren, A. W., Frey, N. V., Nasta, S. D., Goldstein, S. C., Stadtmauer, E. A., Smith, J., Bailey, S., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201248 · Cited by 254
Mikolajczyk, T. P., Nosalski, R., Szczepaniak, P., Budzyn, K., Osmenda, G., Skiba, D., Sagan, A., Wu, J., Vinh, A., Marvar, P. J., et al. (2016) · The FASEB Journal · doi:10.1096/fj.201500088r · Cited by 253
Dexamethasone induces osteoblast apoptosis through ROS-PI3K/AKT/GSK3β signaling pathway
Deng, S., Dai, G., Chen, S., Nie, Z., Zhou, J., Fang, H., & Peng, H. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.11.103 · Cited by 237
Chang, L.-Y., Lin, Y.-C., Mahalingam, J., Huang, C.-T., Chen, T.-W., Kang, C.-W., Peng, H.-M., Chu, Y.-Y., Chiang, J.-M., Dutta, A., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2493 · Cited by 232
Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-Oncology
Jiao, X., Nawab, O., Patel, T., Kossenkov, A. V., Halama, N., Jaeger, D., & Pestell, R. G. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1167 · Cited by 232
Expression of CCL5 (RANTES) and CCR5 in prostate cancer
Vaday, G. G., Peehl, D. M., Kadam, P. A., & Lawrence, D. M. (2006) · The Prostate · doi:10.1002/pros.20306 · Cited by 230
Cancer-FOXP3 directly activated CCL5 to recruit FOXP3+Treg cells in pancreatic ductal adenocarcinoma
Wang, X., Lang, M., Zhao, T., Feng, X., Zheng, C., Huang, C., Hao, J., Dong, J., Luo, L., Li, X., et al. (2017) · Oncogene · doi:10.1038/onc.2016.458 · Cited by 227
Mgrditchian, T., Arakelian, T., Paggetti, J., Noman, M. Z., Viry, E., Moussay, E., Van Moer, K., Kreis, S., Guerin, C., Buart, S., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1703921114 · Cited by 226 · cited 1×
“52 Studies have shown that there is a positive correlation between the level of enhancer of zeste homolog 2 (EZH2) and CCL5.”
Li, M., Sun, X., Zhao, J., Xia, L., Li, J., Xu, M., Wang, B., Guo, H., Yu, C., Gao, Y., et al. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0279-0 · Cited by 225
Yurchenko, E., Tritt, M., Hay, V., Shevach, E. M., Belkaid, Y., & Piccirillo, C. A. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060956 · Cited by 225
The Ras-Erk-ETS-signaling pathway is a drug target for longevity
Slack, C., Alic, N., Foley, A., Cabecinha, M., Hoddinott, M. P., & Partridge, L. (2015) · Cell · doi:10.1016/j.cell.2015.06.023 · Cited by 224
de la Monte, S. M., Longato, L., Tong, M., & Wands, J. R. (2009) · PubMed · Cited by 190
Chemokine receptor CCR5: from AIDS to atherosclerosis
Jones, K., Maguire, J., & Davenport, A. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01147.x · Cited by 184
Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis
Mi, Z., Bhattacharya, S. D., Kim, V. M., Guo, H., Talbot, L. J., & Kuo, P. C. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr009 · Cited by 179
CCL5 increases lung cancer migration via PI3K, Akt and NF-κB pathways
Huang, C.-Y., Fong, Y.-C., Lee, C.-Y., Chen, M.-Y., Tsai, H.-C., Hsu, H.-C., & Tang, C.-H. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.11.014 · Cited by 176
CCR2/CCR5-mediated macrophage–smooth muscle cell crosstalk in pulmonary hypertension
Abid, S., Marcos, E., Parpaleix, A., Amsellem, V., Breau, M., Houssaini, A., Vienney, N., Lefevre, M., Derumeaux, G., Evans, S., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.02308-2018 · Cited by 171
STAT3 induces transcription of the DNA methyltransferase 1 gene (DNMT1) in malignant T lymphocytes
Zhang, Q., Wang, H. Y., Woetmann, A., Raghunath, P. N., Odum, N., & Wasik, M. A. (2006) · Blood · doi:10.1182/blood-2005-08-007377 · Cited by 170
Ban, Y., Mai, J., Li, X., Mitchell-Flack, M., Zhang, T., Zhang, L., Chouchane, L., Ferrari, M., Shen, H., & Ma, X. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2913 · Cited by 166
CCR5/CCL5 axis interaction promotes migratory and invasiveness of pancreatic cancer cells
Singh, S. K., Mishra, M. K., Eltoum, I.-E. A., Bae, S., Lillard, J. W., & Singh, R. (2018) · Scientific Reports · doi:10.1038/s41598-018-19643-0 · Cited by 165
Potential of anti-inflammatory agents for treatment of atherosclerosis
Chistiakov, D. A., Melnichenko, A. A., Grechko, A. V., Myasoedova, V. A., & Orekhov, A. N. (2018) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2018.01.008 · Cited by 165
Nomiyama, H., Osada, N., & Yoshie, O. (2012) · Genes to Cells · doi:10.1111/gtc.12013 · Cited by 164
A Novel RANTES Antagonist Prevents Progression of Established Atherosclerotic Lesions in Mice
Braunersreuther, V., Steffens, S., Arnaud, C., Pelli, G., Burger, F., Proudfoot, A. E. I., & Mach, F. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.165423 · Cited by 164
C-C chemokine receptor type five (CCR5): An emerging target for the control of HIV infection
Barmania, F., & Pepper, M. S. (2013) · Applied & Translational Genomics · doi:10.1016/j.atg.2013.05.004 · Cited by 159
Diet and endometriosis risk: A literature review
Parazzini, F., Viganò, P., Candiani, M., & Fedele, L. (2013) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2012.12.011 · Cited by 159
Wang, S., Liu, S., Sun, H., Huang, T., Chan, C.-H., Yang, C., Yeh, H., Huang, Y., Chou, W., Lin, Y., et al. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu218 · Cited by 156
Aldinucci, D., Lorenzon, D., Cattaruzza, L., Pinto, A., Gloghini, A., Carbone, A., & Colombatti, A. (2007) · International Journal of Cancer · doi:10.1002/ijc.23119 · Cited by 152
Shimizu, S., Hong, P. W.-P., Balamurugan, A., Pokomo, L., Boyer, J., Koizumi, N., Kittipongdaja, P., Chen, A., Bristol, G., Galić, Z., et al. (2009) · Blood · doi:10.1182/blood-2009-04-215855 · Cited by 151
Wang, X., Li, X., Wei, X., Jiang, H., Lan, C., Yang, S., Wang, H., Yang, Y., Tian, C., Xu, Z., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0144-8 · Cited by 151
Self-citationInhibition of the CCL5/CCR5 Axis against the Progression of Gastric Cancer
Aldinucci, D., & Casagrande, N. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051477 · Cited by 150
Weitzenfeld, P., & Ben‐Baruch, A. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.10.006 · Cited by 143
CCR5 Expression Influences the Progression of Human Breast Cancer in a p53-dependent Manner
Mañes, S., Mira, E., Colomer, R., Montero, S., Real, L. M., Gómez‐Moutón, C., Jiménez-Baranda, S., Garzón, A., Lacalle, R. A., Harshman, K., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030580 · Cited by 140
CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion
Jiao, X., Velasco-Velázquez, M. A., Wang, M., Li, Z., Rui, H., Peck, A. R., Korkola, J. E., Chen, X., Xu, S., DuHadaway, J. B., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-0915 · Cited by 138
Mougiakakos, D., Jitschin, R., von Bahr, L., Poschke, I. C., Gary, R., Sundberg, B., Gerbitz, A., Ljungman, P. T., & Blanc, K. L. (2012) · Leukemia · doi:10.1038/leu.2012.215 · Cited by 126
Clinical significance of chemokine receptor antagonists
Miao, M., Clercq, E. D., & Li, G. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1711884 · Cited by 124
Zhang, S., Che, D., Yang, F., Chi, C., Meng, H., Shen, J., Li, Q., Liu, F., Lv, L., Li, Y., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21068 · Cited by 116
The potential to target CCL5/CCR5 in breast cancer
Velasco-Velázquez, M. A., Xolalpa, W., & Pestell, R. G. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.949238 · Cited by 115
Halvorsen, E. C., Hamilton, M. J., Young, A., Wadsworth, B. J., LePard, N. E., Lee, H. N., Firmino, N. S., Collier, J. L., & Bennewith, K. L. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1150398 · Cited by 115
CCL5/CCR5 axis promotes the motility of human oral cancer cells
Chuang, J., Yang, W., Chen, H., Huang, C., Tan, T., Lin, Y., Hsu, C., Fong, Y., & Tang, C. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21783 · Cited by 113
Mast cell degranulation and the role of T cell RANTES in oral lichen planus
Zhao, Z. Z., Sugerman, P. B., Zhou, X. J., Walsh, L. J., & Savage, N. W. (2001) · Oral Diseases · doi:10.1034/j.1601-0825.2001.0070408.x · Cited by 111
Beyond Chemoattraction: Multifunctionality of Chemokine Receptors in Leukocytes
López-Cotarelo, P., Gómez-Moreira, C., Criado‐García, O., Sánchez, L., & Rodríguez‐Fernández, J. L. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.08.004 · Cited by 107
The Expanding Therapeutic Perspective of CCR5 Blockade
Vangelista, L., & Vento, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01981 · Cited by 107
Endothelial Cells Enhance Prostate Cancer Metastasis via IL-6→Androgen Receptor→TGF-β→MMP-9 Signals
Wang, X., Lee, S. O., Xia, S., Jiang, Q., Luo, J., Li, L., Yeh, S., & Chang, C. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0895 · Cited by 103
Bai, J., Gorantla, S., Banda, N. K., Cagnon, L., Rossi, J. J., & Akkina, R. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0038 · Cited by 99
Jin, K., Pandey, N. B., & Popel, A. S. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-0981-3 · Cited by 99
Fray, M. J., DICKINSON, R. P., Huggins, J. P., & Occleston, N. L. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0308038 · Cited by 98
CCL5 and CCR5 Interaction Promotes Cell Motility in Human Osteosarcoma
Wang, S., Wu, H.-H., Liu, S., Wang, P., Ou, W., Chou, W., Shen, Y., & Tang, C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035101 · Cited by 97
Patterson, B. K., Seethamraju, H., Dhody, K., Corley, M. J., Kazempour, K., Lalezari, J., Pang, A. P. S., Sugai, C. K., Francisco, E. B., Pise, A., et al. (2020) · medRxiv · doi:10.1101/2020.05.02.20084673 · Cited by 95
Chan, O., Burke, J. D., Gao, D. F., & Fish, E. N. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.348946 · Cited by 93
Madan, M., Bishayi, B., Hoge, M., & Amar, S. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.02.023 · Cited by 93
Wang, H., Chen, C.-W., Yang, C.-L., Tsai, I.-M., Hou, Y., Chen, C.-J., & Shan, Y. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0295 · Cited by 93
Monocytes, Macrophages, and Osteoclasts in Osteosarcoma
Kelleher, F. C., & O’Sullivan, H. (2017) · Journal of Adolescent and Young Adult Oncology · doi:10.1089/jayao.2016.0078 · Cited by 87
A role for chemokine receptor transactivation in growth factor signaling
Mira, E., Lacalle, R. A., González, M. A., Gómez‐Moutón, C., Abad, J. L., Bernad, A., Martínez‐A, C., & Mañes, S. (2001) · EMBO Reports · doi:10.1093/embo-reports/kve027 · Cited by 86
Cytokine CCL5 and receptor CCR5 axis in glioblastoma multiforme
Kranjc, M. K., Novak, M., Pestell, R. G., & Lah, T. T. (2019) · Radiology and Oncology · doi:10.2478/raon-2019-0057 · Cited by 84
Endothelial cells promote metastasis of prostate cancer by enhancing autophagy
Zhao, R., Bei, X., Yang, B., Wang, X., Jiang, C., Shi, F., Wang, X., Zhu, Y., Jing, Y., Han, B., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0884-2 · Cited by 83
Choi, S. W., Hildebrandt, G. C., Olkiewicz, K. M., Hanauer, D. A., Chaudhary, M. N., Silva, I. A., Rogers, C. E., Deurloo, D. T., Fisher, J. M., Liu, C., et al. (2007) · Blood · doi:10.1182/blood-2007-05-087403 · Cited by 81
Zhang, C., Yang, C., Feldman, M. J., Wang, H., Pang, Y., Maggio, D. M., Zhu, D., Nesvick, C. L., Dmitriev, P., Bullova, P., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18125 · Cited by 80
CCL5 promotes proliferation of MCF-7 cells through mTOR-dependent mRNA translation
Murooka, T. T., Rahbar, R., & Fish, E. N. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.07.035 · Cited by 78
Pérez‐Martínez, L., Pérez‐Matute, P., Aguilera‐Lizarraga, J., Rubio-Mediavilla, S., Narro-Íñiguez, J., Recio, E., Ochoa‐Callejero, L., Oteo, J. A., & Blanco, J. R. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku071 · Cited by 76
Mencarelli, A., Cipriani, S., Francisci, D., Santucci, L., Baldelli, F., Distrutti, E., & Fiorucci, S. (2016) · Scientific Reports · doi:10.1038/srep30802 · Cited by 76
CC Chemokine Receptor 5: The Interface of Host Immunity and Cancer
de Oliveira, C. E. C., Oda, J. M. M., Guembarovski, R. L., de Oliveira, K. B., Ariza, C. B., Neto, J. S., Hirata, B. K. B., & Watanabe, M. A. E. (2014) · Disease Markers · doi:10.1155/2014/126954 · Cited by 75
Elevated Expression of Angiogenin in Prostate Cancer and Its Precursors
Katona, T. M., Neubauer, B. L., Iversen, P. W., Zhang, S., Baldridge, L. A., & Liang Cheng, C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0962 · Cited by 75
Increasing CCL5/CCR5 on CD4+ T cells in peripheral blood of oral lichen planus
Hu, J., Zhang, J., Cui, J.-L., Liang, X., Lü, R., Du, G., Xu, X.-Y., & Zhou, G. (2013) · Cytokine · doi:10.1016/j.cyto.2013.01.020 · Cited by 74
Mellado, M., de Ana, A. M., Moreno, M. C., Martínez‐A, C., & Rodríguez-Frade, J. M. (2001) · Current Biology · doi:10.1016/s0960-9822(01)00199-3 · Cited by 72
PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy
Romano, A., Parrinello, N. L., Cava, P. L., Tibullo, D., Giallongo, C., Camiolo, G., Puglisi, F., Parisi, M. S., Pirosa, M. C., Martino, E. A., et al. (2018) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1470929 · Cited by 72
NF-κB binds to a polymorphic repressor element in the MMP-3 promoter
Borghaei, R. C., Rawlings, P. L., Javadi, M., & Woloshin, J. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.02.030 · Cited by 69
Landovitz, R. J., Angel, J. B., Hoffmann, C., et al. (2008) · The Journal of Infectious Diseases · doi:10.1086/592052 · Cited by 69
Fleishaker, D. L., Meijide, J. A. G., Av, P., Kohen, M. D., Wang, X., Menon, S. S., Stock, T. C., Mebus, C. A., Goodrich, J. M., Mayer, H., et al. (2012) · Arthritis Research & Therapy · doi:10.1186/ar3685 · Cited by 68
Ligand-receptor interaction atlas within and between tumor cells and T cells in lung adenocarcinoma
Chen, Z., Yang, X., Bi, G., Liang, J., Hu, Z., Zhao, M., Li, M., Lu, T., Zheng, Y., Sui, Q., et al. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.42080 · Cited by 66
Chen, Y., Hu, Y. Y., Yang, L., Zhou, J., Tang, Y., Zheng, L., & Qin, P. (2017) · Cell Biology International · doi:10.1002/cbin.10779 · Cited by 65
Agresti, N., Lalezari, J. P., Amodeo, P. P., Mody, K., Mosher, S. F., Seethamraju, H., Kelly, S. A., Pourhassan, N. Z., Sudduth, C. D., Bovinet, C., et al. (2021) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2021.100083 · Cited by 65
CCR5/CD4/CXCR4 oligomerization prevents HIV-1 gp120 IIIB binding to the cell surface
Martínez‐Muñoz, L., Barroso, R., Dyrhaug, S. Y., Navarro, G., Lucas, P., Soriano, S. F., Vega, B., Costas, C., Muñoz‐Fernández, M. Á., Santiago, C. A., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1322887111 · Cited by 64
Tanabe, Y., Sasaki, S., Mukaida, N., & Baba, T. (2016) · Oncotarget · doi:10.18632/oncotarget.10227 · Cited by 63
Involvement of matrix metalloproteinase-3 in CCL5/CCR5 pathway of chondrosarcomas metastasis
Tang, C., Yamamoto, A., Lin, Y., Fong, Y., & Tan, T. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.08.006 · Cited by 61
Pfleger, C., Kaas, A., Hansen, L., Alizadeh, B. Z., Hougaard, P., Holl, R. W., Kolb, H., Roep, B. O., Mortensen, H. B., & Schloot, N. C. (2008) · Clinical Immunology · doi:10.1016/j.clim.2008.03.458 · Cited by 60
Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study
Eksteen, B., Bowlus, C. L., Montaño‐Loza, A. J., Lefebvre, E. A., Fischer, L., Vig, P., Martins, E. B., Ahmad, J., Yimam, K. K., Pockros, P. J., et al. (2020) · Hepatology Communications · doi:10.1002/hep4.1619 · Cited by 60
EZH2 enhances expression of CCL5 to promote recruitment of macrophages and invasion in lung cancer
Xia, L., Zhu, X., Zhang, L., Xu, Y., Chen, G., & Luo, J. (2019) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.1875 · Cited by 59
van der Vorst, E. P. C., Vanags, L. Z., Dunn, L., Prosser, H. C. G., Rye, K., & Bursill, C. A. (2012) · The FASEB Journal · doi:10.1096/fj.12-212753 · Cited by 58
CCR5 inhibitors: emergence, success, and challenges
Maeda, K., Das, D., Nakata, H., & Mitsuya, H. (2012) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2012.673584 · Cited by 58
Liou, J.-T., Mao, C.-C., Sum, D. C.-W., Liu, F.-C., Lai, Y.-S., Li, J.-C., & Day, Y. (2012) · Journal of Pain · doi:10.1016/j.jpain.2012.09.015 · Cited by 57
Antiretroviral Therapy Exposure and Insulin Resistance in the Women's Interagency HIV Study
Tien, P. C., Schneider, M. F., Cole, S. R., Levine, A. M., Cohen, M. H., DeHovitz, J. A., Young, M., & Justman, J. E. (2008) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318189a780 · Cited by 57
TALEN-Mediated Knockout of CCR5 Confers Protection Against Infection of Human Immunodeficiency Virus
Shi, B., Li, J., Shi, X., Jia, W., Wen, Y., Hu, X., Zhuang, F., Xi, J., & Zhang, L. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001190 · Cited by 56
Advances of CCR5 antagonists: From small molecules to macromolecules
Qi, B., Fang, Q., Liu, S., Hou, W., Li, J., Huang, Y., & Shi, J. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112819 · Cited by 56
Zhang, X., Haney, K. M., Richardson, A. C., Wilson, E. N., Gewirtz, D. A., Ware, J. L., Zehner, Z. E., & Zhang, Y. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.06.003 · Cited by 51
CCR5 blockage by maraviroc induces cytotoxic and apoptotic effects in colorectal cancer cells
Pervaiz, A., Ansari, S. S., Berger, M. R., & Adwan, H. (2015) · Medical Oncology · doi:10.1007/s12032-015-0607-x · Cited by 51
Safety concerns about CCR5 as an antiviral target
Telenti, A. (2009) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e3283223d76 · Cited by 50
Chou, S., Ajoy, R., Changou, C. A., Hsieh, Y.-T., Wang, Y.-K., & Hoffer, B. J. (2016) · Scientific Reports · doi:10.1038/srep37659 · Cited by 48
CCR5 status and metastatic progression in colorectal cancer
Suarez‐Carmona, M., Chaorentong, P., Kather, J. N., Rothenheber, R., Ahmed, A., Berthel, A., Heinzelmann, A., Moraleda, R. R., Valous, N. A., Koşaloğlu‐Yalçın, Z., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1626193 · Cited by 48
Yang, T., Chen, M., Yang, X., Zhang, X., Zhang, Z., Sun, Y., Xu, B., Hua, J., He, Z., & Song, Z. (2017) · Cancer Biology & Therapy · doi:10.1080/15384047.2017.1373219 · Cited by 47
Fang, R., Zhang, G., Guo, Q., Ning, F., Wang, H., Cai, S., & Du, J. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.01.014 · Cited by 45
Xiong, Y., Torsoni, A. S., Wu, F., Shen, H., Liu, Y., Zhong, X. Y., Canet, M. J., Shah, Y. M., Omary, M. B., Liu, Y., et al. (2018) · eLife · doi:10.7554/elife.34152 · Cited by 45
Liu, J., Wang, C., Ma, X., Tian, Y., Wang, C., Fu, Y., & Luo, Y. (2018) · The Journal of Pathology · doi:10.1002/path.5207 · Cited by 44
Caseiro, M. M., Nelson, M. R., Diaz, R. S., Gathe, J., Neto, J. L. D. A., Slim, J., Solano, A., Netto, E. M., Mak, C., Shen, J., et al. (2012) · Journal of Infection · doi:10.1016/j.jinf.2012.05.008 · Cited by 43
Lin, A. A., Tripathi, P., Sholl, A., Jordan, M. B., & Hildeman, D. A. (2009) · Journal of Virology · doi:10.1128/jvi.02477-08 · Cited by 42
Ramírez-Martínez, G., Cruz‐Lagunas, A., Jiménez-Álvarez, L. A., Espinosa, E., Ortíz-Quintero, B., Santos-Mendoza, T., Herrera, M. T., Canché-Pool, E. B., Mendoza-Milla, C., Bañales, J. L., et al. (2013) · Cytokine · doi:10.1016/j.cyto.2013.01.018 · Cited by 42
CCL5-CCR5 interactions modulate metabolic events during tumor onset to promote tumorigenesis
Gao, D. F., Cazares, L. H., & Fish, E. N. (2017) · BMC Cancer · doi:10.1186/s12885-017-3817-0 · Cited by 42
Pervaiz, A., Zepp, M., Georges, R. B., Bergmann, F., Mahmood, S., Faiza, S., Berger, M. R., & Adwan, H. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03382-9 · Cited by 42
Li, Y., Liu, X., Duan, W., Tian, H., Zhu, G., He, H., Yao, S., Yi, S., Song, W., & Tang, H. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.04.008 · Cited by 41
The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro
Okamoto, M., Toyama, M., & Baba, M. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104902 · Cited by 41
Zhang, Z., Dong, J., Lobe, C. G., Gong, P., Liu, J., & Liao, L. (2015) · Stem Cell Research & Therapy · doi:10.1186/s13287-015-0026-0 · Cited by 39
Makinoshima, H., & Dezawa, M. (2009) · FEBS Letters · doi:10.1016/j.febslet.2009.10.061 · Cited by 35
Expression and biological functions of the CCL5‐CCR5 axis in oral lichen planus
Shan, J., Li, S., Wang, C., Liu, L., Wang, X., Zhu, D., Yuan, F., & Xu, J. (2019) · Experimental Dermatology · doi:10.1111/exd.13946 · Cited by 32
Autocrine CCL5 promotes tumor progression in esophageal squamous cell carcinoma in vitro
Wu, Y., Shen, Y., Chang, J. W., Hsieh, J., Chu, Y., & Wang, C. (2018) · Cytokine · doi:10.1016/j.cyto.2018.04.027 · Cited by 30
Research Trends and Regulation of CCL5 in Prostate Cancer
Huang, R., Guo, L., Gao, M., Li, J., & Xiang, S. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s279189 · Cited by 30
Wierda, R. J., Kuipers, H. F., van Eggermond, M. C. J. A., Benard, A., van Leeuwen, J. C., Carluccio, S., Geutskens, S. B., Jukema, J. W., Márquez, V. E., Quax, P. H. A., et al. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01482.x · Cited by 28
Guo, P., Bi, K., Lu, Z., Wang, K., Xu, Y., Wu, H., Cao, Y., & Jiang, H. (2019) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2019.05.014 · Cited by 28
Zoledronic acid causes γδ T cells to target monocytes and down‐modulate inflammatory homing
Fowler, D. W., Copier, J. P., Dalgleish, A. G., & Bodman‐Smith, M. D. (2014) · Immunology · doi:10.1111/imm.12331 · Cited by 27
Zhang, Y., Arnatt, C. K., Zhang, F., Wang, J., Haney, K. M., & Fang, X. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.05.127 · Cited by 24
D’Antoni, M. L., Mitchell, B. I., McCurdy, S., Byron, M. M., Ogata-Arakaki, D., Chow, D. C., Mehta, N. N., Boisvert, W. A., Lefebvre, E. A., Shikuma, C. M., et al. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.5a0817-328rrr · Cited by 24
Wasylyk, C., Criqui-Filipe, P., & Wasylyk, B. (2004) · Oncogene · doi:10.1038/sj.onc.1208226 · Cited by 19
Yang, T., Li, J., Li, R., Yang, C., Zhang, W., Qiu, Y., Yang, C., & Rong, R. (2019) · Current Gene Therapy · doi:10.2174/1566523219666190618093707 · Cited by 18
Xu, L., Wang, H., Gong, Y., Pang, M., Sun, X., Guo, F., & Gao, S. (2016) · Metabolism · doi:10.1016/j.metabol.2016.10.010 · Cited by 13
Nganvongpanit, K., Chaochird, P., Siengdee, P., Pothacharoen, P., Klunklin, K., Chomdej, S., Mekchay, S., & Kongtawelert, P. (2009) · Journal of Orthopaedic Surgery and Research · doi:10.1186/1749-799x-4-45 · Cited by 8
Dong, B., Ding, Y., Huang, Q., & Guan, X. (2019) · Medical Science Monitor · doi:10.12659/msm.911689 · Cited by 5
Li, M., Lu, C., Zhu, H., Kang, X., Wang, F., Shao, L., Lu, X., Chen, W., & Xia, X. (2019) · Europe PMC (PubMed Central) · Cited by 2
Cited by
Targeting cytokine and chemokine signaling pathways for cancer therapy
Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01868-3 · Cited by 455
A high-resolution analysis of arrestin2 interactions responsible for CCR5 endocytosis
(2025) · doi:10.7554/elife.106839 · Cited by 1
A high-resolution analysis of arrestin2 interactions responsible for CCR5 endocytosis
Petrovic, I., Desai, S., Isaikina, P., Abiko, L. A., Spang, A., & Grzesiek, S. (2026) · eLife · doi:10.7554/elife.106839.4
Metadata
- Authors
- Zeng, Z., Lan, T., Wei, Y., & Wei, X.
- Venue
- Genes & Diseases
- Publisher
- Elsevier BV
- Published
- 2022-01
- Volume
- 9
- Issue
- 1
- Pages
- 12-27
- ISSN
- 2352-3042 (ISSN-L)
- OpenAlex
- W3198637955
- Cited by
- 378
- References
- 178
- FWCI
- 17.69
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.